SNStephen Eric Nybo

Stephen Eric Nybo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen Eric Nybo has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities

    by Rongbin Wang, Heli Tirkkonen, Sabina Y. van der Zanden, Larissa Ponomareva, Isaline Fagon, Leslie Fève, Kendall Paige, Courtney L. Brown, Nora Schwartz, Jacob Hecht, et al.

    Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.

  • Open Access

    Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities

    by Rongbin Wang, Heli Tirkkonen, Sabina Y. van der Zanden, Larissa Ponomareva, Isaline Fagon, Leslie Fève, Kendall Paige, Courtney L. Brown, Nora Schwartz, Jacob Hecht, et al.

    Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.

  • Open Access

    Refining genetic circuit design for enhanced type II polyketide biosynthesis in Escherichia coli

    by Zeynab Aghabayli, Isabel Henige, Megan Ley, Oona Nieminen, Courtney L. Brown, Rongbin Wang, Alexis Bruglio, Xuechen Zhu, Mikko Metsä-Ketelä, S. Eric Nybo

  • Open Access

    Comprehensive review of β-carbolines from microbes and their biosynthesis

    by Mary Ayeko Twumasi, Matthew Peter Kusche, Amna Farzeen Baig, S. Eric Nybo, Madan Kumar Kharel


  • Open Access

    Metabolic engineering of doxorubicin biosynthesis through P450-redox partner optimization and structural analysis of DoxA

    by Arina Koroleva, Erika Artukka, Keith Yamada, Sean A. Newmister, Ralph J. Harte, Hannah Boesger, Mikael Londen, Jacob N. Sanders, Heli Tirkkonen, Matti Kannisto, et al.

    Doxorubicin, a widely used chemotherapy drug, is produced by Streptomyces peucetius ATCC27952. The biosynthesis relies on the cytochrome P450 monooxygenase DoxA, which catalyzes three consecutive late-stage oxidation steps. However, conversion from daunorubicin to doxorubicin is inefficient, necessitating semi-synthetic industrial manufacturing. Here, we address key limitations in DoxA catalysis. We identify the natural redox partners ferredoxin Fdx4 and ferredoxin reductase FdR3 by transcriptomic analysis. We discovered the vicinal oxygen chelate family protein DnrV to prevent product inhibition by binding doxorubicin. Structural analysis of DoxA and density functional theory (DFT) calculations reveal that inefficient C14 hydroxylation results from the unfavorable anti-conformation of the methyl ketone side chain of daunorubicin. We harness these advances for rational strain engineering, leading to an 180% increase in doxorubicin yields and an improved production profile. This study provides singular insights into enzymatic constraints in anthracycline biosynthesis and facilitates cost-effective manufacturing to meet the growing global demand for doxorubicin.


  • Open Access

    Tetracenomycin Aglycones Primarily Inhibit Cell Growth and Proliferation in Mammalian Cancer Cell Lines

    by Kyah Birdsall, Adwowa B. S. Brako, Courtney Brown, Kendall Paige, Alexis West, Nora Schwartz, Jacob Hecht, Katelyn V. Brown, Jon S. Thorson, Khaled A. Shaaban, et al.

    Tetracenomycins are anticancer polyketides that arrest cancer cell proliferation via binding to the large mammalian ribosomal subunit near the polypeptide exit channel. The tetracenomycins are natural products that many members of the actinomycete family produce. The first goal of this study was to improve the biosynthesis of tetracenomycin analogs via metabolic engineering. The second goal was to probe more deeply into the antiproliferative activity of tetracenomycin aglycones. The tetracenomycins were assessed via several assays, including cell viability assays, clonogenic assays, and flow cytometry apoptosis assays. The data suggest that tetracenomycins C and X inhibit cell proliferation and arrest cell growth, supporting their cytostatic action mechanism. In addition, tetracenomycins C and X induced degeneration of 3D spheroid cultures and exhibited concentration-dependent inhibition of cell survival and colony formation in clonogenic assays. This work demonstrates that tetracenomycins act mainly as cytostatic rather than apoptotic agents.


  • Open Access

    Refining genetic circuit design for enhanced type II polyketide biosynthesis in Escherichia coli

    by Zeynab Aghabayli, Isabel Henige, Megan Ley, Courtney L. Brown, Oona Nieminen, Kendall Paige, Alicia Brock, Hope McGillis, Hope Flowers, Alexis Bruglio, et al.

    Polyketides represent a broad class of structurally diverse natural products with potent antibacterial and anticancer activities. Type II polyketide synthases (T2PKS) are multi-subunit complexes responsible for condensing acylated intermediates, including acetyl-CoA and malonyl-CoA, into complex fused-ring aromatic natural products. While type II polyketides have traditionally been associated with gram-positive actinomycetes, more recent discoveries have identified PKS systems in gram-negative bacteria. These findings have provided new genetic tools and opened new pathways for producing and manipulating polyketides in the versatile chassis organism Escherichia coli. In this study, we altered the genetic circuit of the Photorhabdus luminescens PKS for octaketide production in E. coli. Promoter engineering and ribosome binding site optimization of the antDEFBG minimal PKS (mPKS) resulted in 181 mg/L SEK4 and 392 mg/L SEK4b production titers. Further refinement of downstream ketoreductase, aromatase, and cyclase expression enabled the biosynthesis of native polyketide AQ-256 and naphthopyrone (S)-DNPA at titers exceeding 200 mg/L/d. Additional metabolic reprogramming strategies further increased yields by 25%. This work further illustrates the potential of E. coli as a versatile host for the biosynthesis of complex polyketides, paving the way for the scalable production of valuable natural products. By optimizing genetic circuits and pathway expression, this study provides a test case for engineering microbial systems to produce pharmaceutically relevant compounds more efficiently.

  • Open Access

    Three-Enzyme Cascade Catalyzes Conversion of Auramycinone to Resomycin in Chartreusin Biosynthesis

    by Magdalena Niemczura, Aleksi Nuutila, Rongbin Wang, Katariina Rauhanen, S. Eric Nybo, Mikko Metsä-Ketelä

    Chartreusin is a potent antiproliferative agent that contains a unique aromatic pentacyclic bislactone carbon scaffold. The biosynthesis of type II polyketide aglycone has been extensively investigated and shown to proceed through a tetracyclic anthracycline intermediate. The last remaining unknown steps are the conversion of auramycinone to resomycin C. Here we have discovered three enzymes that play crucial roles in two mechanistically distinct dehydration reactions. We show that ChaX is an NAD(P)H-dependent auramycinone quinone reductase that allows the cyclase-like ChaU to catalyze the formation of 9,10-dehydroauramycinone via a carbanion intermediate. In contrast, the cyclase-like ChaJ, homologous to ChaU, is responsible for subsequent 7,8-dehydration via a canonical carbocation intermediate, yielding resomycin C. The results were confirmed via assembly of the biosynthetic pathway for production of resomycin C in Streptomyces coelicolor M1152ΔmatAB. The work expands the catalytic repertoire of the SnoaL protein family, which has previously been associated with anthracycline fourth-ring cyclization and two-component 1-hydroxylation.


  • Open Access

    Complete sequences of pIJ101-based Streptomyces-Escherichia coli shuttle vectors

    by Katelyn V. Brown, S. Eric Nybo

    High-copy-number plasmids are indispensable tools for gene overexpression studies in prokaryotes to engineer pathways or probe phenotypes of interest. The development of genetic tools for the industrially relevant Actinobacteria is of special interest, given their utility in producing keratolytic enzymes and biologically active natural products. Within the Actinobacteria, Streptomyces–Escherichia coli shuttle vectors based on the SCP2* and pIJ101 incompatibility groups are widely employed for molecular cloning and gene expression studies. Here, the sequences of two commonly used pIJ101-based Streptomyces–E. coli shuttle vectors, pEM4 and pUWL201, were determined using next-generation sequencing. These plasmids drive the expression of heterologous genes using the constitutive ermE*p promoter. pEM4 was found to be 8.3 kbp long, containing a β-lactamase gene, thiostrepton resistance marker, the lacZɑ fragment, a ColE1 origin of replication and the Streptomyces pIJ101 origin of replication. pUWL201 was found to be 6.78 kbp long, containing a β-lactamase gene, thiostrepton resistance marker, the lacZɑ fragment, a ColE1 origin of replication and the Streptomyces pIJ101 origin of replication. Interestingly, the sequences for both pEM4 and pUWL201 exceed their previously reported size by 1.1 and 0.4 kbp, respectively. This report updates the literature with the corrected sequences for these shuttle vectors, ensuring their compatibility with modern synthetic biology cloning methodologies.


  • Open Access

    Complete sequences of pIJ101-based Streptomyces-E. coli shuttle vectors

    by Katelyn Victoria Brown, Stephen Eric Nybo

    High-copy number plasmids are indispensable tools for gene overexpression studies in prokaryotes to engineer pathways or probe phenotypes of interest. The development of genetic tools for the industrially-relevant Actinobacteria is of special interest, given their utility in producing keratolytic enzymes and biologically active natural products.Within the Actinobacteria, Streptomyces-Escherichia coli shuttle vectors based on the SCP2* and pIJ101 incompatibility groups are widely employed for molecular cloning and gene expression studies. Here, the sequences of two commonly used pIJ101-based Streptomyces-E. coli shuttle vectors, pEM4 and pUWL201, were determined using next-generation sequencing. These plasmids drive the expression of heterologous genes using the constitutive ermE*p promoter. pEM4 was found to be 8.3 kbp long, containing a β-lactamase gene, thiostrepton resistance marker, the lacZɑ fragment, a ColE1 origin of replication, and the Streptomyces pIJ101 origin of replication. pUWL201 was found to be 6.78 kbp long, containing a β-lactamase gene, thiostrepton resistance marker, the lacZɑ fragment, an ColE1 origin of replication, and the Streptomyces pIJ101 origin of replication. Interestingly, the sequences for both pEM4 and pUWL201 exceed their previously reported size by 1.1 kbp and 0.4 kbp, respectively. This report updates the literature with the corrected sequences for these shuttle vectors, ensuring their compatibility with modern synthetic biology cloning methodologies.